Abstract: Objective: The aim of this study was to investigate the methylenetetrahydrofolate reductase (MTHFR) gene rs1801133 C>T polymorphisms and lung cancer susceptibility by pooling openly published data.
Introduction
Global cancer statistical analysis has found that lung cancer, including non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), was the leading cause of malignant carcinoma related death in males and females worldwide in 2016 [1] . In females, the incidence of lung cancer is second only to breast cancer but is the first in males [2] [3] [4] . Cigarette smoking was confirmed as the leading cause of carcinogenesis in lung cancer patients. However, genetic factors including oncogenes, tumor suppressor genes and metabolic enzyme gene polymorphisms also play an important role in the development of lung cancer.
Methylenetetrahydrofolate reductase is a key enzyme in the folate metabolism pathway coded by MTHFR gene [5, 6] . Methylenetetrahydrofolate reductase irreversibly converts folic acid metabolite 5, 10-methylenetetrahydrofolic acid to 5-methyltetrahydrofolic acid and further provides the materials for DNA synthesis. MTHFR rs1801133 C>T is one the most common polymorphism SNP sites which cause alanine to be replaced with valine and reduces enzyme activity and heat resistance. Correlations between MTHFR gene rs1801133 C>T polymorphisms and cancer susceptibility has been widely discussed in lung cancer [7, 8] , esophageal cancer [9, 10] , colorectal cancer [11, 12] , breast cancer [13] , and other cancers. MTHFR gene rs1801133 C>T polymorphisms and lung cancer risk was evaluated by several case-control studies with inconclusive results [7, 8] . Therefore, we performed this updated meta-analysis.
Material and Methods

Search strategy
Electronic databases of Medline, Web of Science, Embase, Google scholar, CBM and CNKI were systematic searched to find the relevant studies related to MTHFR gene rs1801133 C>T polymorphisms and lung cancer susceptibility. The publication identification process was performed according to the Cochrane handbook and demonstrated by Figure 1 . The terms "lung cancer OR carcinoma of the lung OR non-small cell lung cancer OR NSCLC" AND "methylenetetrahydrofolate reductase OR MTHFR", were used to identify relevant studies.
Study selection criteria
The inclusion criteria used to screen all identified articles were: (1) lung cancer, including non-small cell lung cancer and small cell lung cancer, was confirmed by pathology or clinical diagnosis; (2) the controls were healthy subjects without any malignant diseases; (3) the genotype of the lung cancer and controls could be extracted from original studies; (4) the study type was either a case-control study or a cohort study; (5) the studies were published in English or Chinese.
Data extraction and critical appraisal
Two reviewers carefully read the included full-text papers and extracted the eligible information and data independently according to the Cochrane Handbook. The extracted information and data included: (1) first and corresponding authors; (2) year of publication; (3) region of the work performed; (4) ethnicity of the included subjects; (5) control type (hospital-based or population-based); (6) Hardy-Weinberg equilibrium (HWE) of the control group; (7) TT, CT and CC allele frequency in original study of the case and control groups.
Statistical analysis
The odds of TT, CT and CC alleles in lung cancer patients compared with healthy controls were pooled by the effect size of odds ratio (OR) and corresponding 95% confidence interval (95%CI) under random or fixed effect model. The statistical heterogeneity of the included publications in each genetic model was assessed by I 2 test. The OR was pooled by random or fixed effect model according to statistical heterogeneity. The publication bias was evaluated by Begg's funnel plot and Egger's line regression test [14] . All the data analysis was performed using STATA/SE 11.0 software (http://www.stata.com; Stata Corporation, College Station, TX). A two-tailed p-value less than 0.05 was considered statistically significant.
Results
General characteristics of the included publications
After systematically searching the electronic databases, a total of 21 studies were included in the present metaanalysis. The main characteristics of the studies were shown in Table 1 .
Statistical heterogeneity analysis
The statistical heterogeneity of the effect size in each different genetic model was assessed by I 2 test. Significant statistical heterogeneity was found in the dominant, recessive and homologous genetic models ( Table 2 ). 
Meta-analysis Dominant genetic model (TT+CT vs CC)
In the dominant genetic model (TT+CT vs CC), subjects with TT or CT alleles had an elevated risk of developing lung cancer (OR=1.14, 95%CI:1.01-1.28, p<0.05) by pooling data with random effect method (Figure 2 ). Significant publication bias was observed in the dominant genetic model evaluated by Begg's funnel plot (Figure 3 ) and Egger's line regression test (t=2.44, p=0.025).
Recessive genetic model (TT vs CT+CC)
Under the recessive genetic model (TT vs CT+CC), lung cancer risk was significantly increased in subjects with TT allele compared to CC/CT (OR=1.26, 95%CI:1.08-1.48, p<0.01) in random effect model (Figure 4 ). Begg's funnel plot ( Figure 5 ) and Egger's line regression test (t=2.67, p=0.015) demonstrated significant publication bias.
Homologous model (TT vs CC)
In the homologous model (TT vs CC), increased lung cancer risk was found in the population with TT allele compared to CC with statistical difference (OR=1.36, 95%CI:1.12-1.65, p<0.01) in random effect model. Significant publication bias was determined by Begg's funnel plot (Figure 7 ) and Egger's line regression test (t=2.93, p=0.009).
Discussion
In 2001, the relationship between MTHFR gene polymorphism and susceptibility to lung cancer was examined for the first time in non-Spanish Caucasians by Shen et al. [33] . It was concluded that MTHFR gene C677T (rs1801133 C>T) and A1298C polymorphisms were not associated with lung cancer. Jeng et al. [31] in 2003 also suggested that C677T locus of MTHFR gene had no risk effect on lung cancer susceptibility. Mao et al. [34] in 2008 and Boccia et al. [35] in 2009 conducted a meta-analysis of the association of MTHFR gene C677T and A1298C polymorphisms with lung cancer susceptibility. However, the correlation between MTHFR gene C677T (rs1801133 C>T) polymorphisms has not been identified as yet. In 2012, Hou et al [36] performed an up-date meta-analysis relevant to MTHFR gene C677T polymorphisms and lung cancer risk and found the correlation. In Hou's study, the authors found that the MTHFR 677T null genotype (T vs C) may increase NSCLC risk. However, 6 years had passed since Hou et al., reported their work and several new studies had been published. Therefore, we performed this updated meta-analysis by including the new publications relevant to MTHFR gene C677T polymorphisms and lung cancer risk in order to further elucidate the correlation. Here, the data from 21 publications relating to MTHFR gene C677T polymorphisms and lung cancer risk were pooled. We determined T allele frequency in lung cancer patients was higher when compared to healthy controls in all gene expression models, indicating that populations with T alleles had an increased risk of developing lung cancer in all genetic models which were in accordance with Hou et al., results. However, compared to Hou et al., we discussed the correlation between MTHFR gene C677T polymorphisms and lung cancer in dominant, recessive and homologous genetic models and also added 4 newly published studies which were not included in Hou et al. Although the results of the present meta-analysis were similar to Hou et al., our study provided further evidence for the potential correlation between MTHFR gene C677T polymorphisms and lung cancer susceptibility. Our work concluded that T allele increased the lung cancer risk compared to C. However, there are several limitations for the present study. Firstly, the statistical heterogeneity was observed in all genetic models, and the data were pooled by a random effect model. The statistical power is weaker than the fixed effect model. Secondly, significant publication bias was found in the meta-analysis which indicating studies with negative results may not be published. The heterogeneity across the included studies was potentially from two major aspects. One is from the clinical heterogeneity such as the subjects included in each study were varied in gender and ethnicity. The second clinical heterogeneity may come from the control types (hospital-based or population-based) and the third source of clinical heterogeneity may be due to the different methods of genotyping detection. The other major aspect of heterogeneity was statistical heterogeneity. The statistical heterogeneity may have arisen in describing the properties of a dataset, or several datasets. They relate to the validity of the often-convenient assumption that the statistical properties of any one part of an overall dataset are the same as any other part. In a meta-analysis which combines the data from several studies, homogeneity measures the differences or similarities between the several studies.
Methylenetetrahydrofolate reductase is a key enzyme in the folate metabolism pathway coded by the MTHFR gene which plays a key role in folate metabolism, catalyzing the irreversible conversion of 5,10-MTHF to 5-MTHF. MTHFR rs1801133 C>T can cause alanine to be replaced with valine, which reduces enzyme activity. Reduced MTHFR activity generally leads to increased 5,10-MTHF for DNA synthesis and decreased 5-MTHF for DNA methylation and finally increased the cancer risk [6, 20] .
Conclusion
Based on the present data, lung cancer susceptibility may be increased in subjects with TT or CT alleles, compared to CC alleles. However, due to the statistical heterogeneity and publication bias limitations, conclusions should be drawn with caution. We recommend more well-designed original case-control studies, cohort studies or highquality meta-analysis relevant to (MTHFR) gene rs1801133 C>T polymorphisms and lung cancer susceptibility in order to further elucidate its correlation. 
